跳至主要内容
临床试验/NCT00485368
NCT00485368已完成3 期

The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.

Bayside Health0 个研究点目标入组 17 人开始时间: 2004年1月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
17
主要终点
aortic root diameter

研究概览

简要总结

The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-40
  • Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria

排除标准

  • Age <18, >40
  • Women of child-bearing potential not on adequate contraception
  • Serum creatinine of >0.11
  • A history of intolerance to ACEI
  • Patients on angiotensin receptor blockers
  • Blood pressure >140/90mmHg
  • History of previous aortic surgery

结局指标

主要结局

aortic root diameter

时间窗: 24 weeks

次要结局

  • arterial stiffness(24 weeks)

研究者

发起方
Bayside Health
申办方类型
Other Gov

相似试验